Tiorfan (racecadotril) / Bioprojet - LARVOL DELTA

Racecadotril Ameliorates 4-HNE-Induced Endothelial Dysfunction in Hypoplastic Left Heart Syndrome (AHA 2026) - No abstract available

Cardiovascular

Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (clinicaltrials.gov) - P=N/A | N=48 | Completed | Sponsor: Queen Mary University of London | Active, not recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Inflammation • Pulmonary Disease • Respiratory Diseases • CXCL8

RACECADOTRIL AS A NEW MOLECULE IN THE TREATMENT OF LOW ANTERIOR RESECTION SYNDROME (UEGW 2026) - "Full abstract will be published on the day of presentation"

Late-breaking abstract

THE PRACTICAL CASE OF RACECADOTRIL FOR A MULTIVARIATE META-ANALYTICAL DEVELOPMENT OF A PREDICTING MODEL OF CHILDREN ACUTE GASTROENTERITIS ASSESSING THE EFFICACY OF ORS ADJUNCT TREATMENTS (UEGW 2026) - "This first predictive model on CAGE provided evidence of a strong determination considerably increasing the statistical power of 37.6%, and its use as a predicting mode in routine practice is justified by its high discrimination. The negative synergetic interaction effect of dehydration level and Rotavirus etiology highlights the importance of rapid intervention. Based on this adjustment, compared with placebo control, the efficacy of racecadotril is summarized by a decrease of 31% of diarrhea duration (GMR=0.69), and increase of 78% of responders (RB=1.78)."

Clinical • Gastroenterology • Gastrointestinal Disorder • Rotavirus Infections

Efficacy and Safety of Racecadotril in Pediatric Acute Diarrhea: An Updated Systematic Review and Meta-analysis (ACG 2026) - "13 RCTs involving 3,227 children (racecadotril n=1,625; control n=1,602) were included. Racecadotril showed a non-significant reduction in IV fluid requirement (RR=0.55, 95% CI: 0.29â1.06, I²=33%). Vomiting as an adverse event was comparable between groups (RR=1.06, 95% CI: 0.81â1.38, I²=0%)."

Retrospective data • Review • Pediatrics • PENK

Intestinal Failure-Associated Liver Disease in a Child With Short Bowel Syndrome: Management Issues (ACG 2026) - "Stool cultures grew multidrug-resistant E. coli , treated with IV colistin and amikacin. Despite targeted antibiotics, diarrhea persisted, requiring amino acid-based formula, racecadotril, loperamide, and pantoprazole...Management included UDCA (bile salt inhibition, hepatoprotection), pantoprazole (short-term, for hypergastrinemia-driven losses), rifaximin (empirical SIBO treatment), and DHA (promotes adaptation, reduces cholestasis)...Figure: Table 1: Serial investigations of the patient. Note: PTBD: Percutaneous transhepatic biliary drainage, CRP: C-reactive protein, SGOT: Serum glutamate oxaloacetate transferase, SGPT: Serum glutamate pyruvate transferase, ALP: Alkaline phosphatase, GGT: Gamma glutamyl transferase."

Clinical • Cholestasis • Gastrointestinal Disorder • Hepatology • Hypoglycemia • Infectious Disease • Short Bowel Syndrome • CRP

ERADICATE: Racecadotril Versus Standard Treatment in Decreasing the Duration of Acute Diarrhoea in Children (clinicaltrials.gov) - P1/2 | N=260 | Completed | Sponsor: Benazir Bhutto Hospital, Rawalpindi | Not yet recruiting ➔ Completed

Trial completion

Management of Acute Diarrhea in Children after Implementing the Thai Clinical Practice Guideline. (PubMed, Pediatr Gastroenterol Hepatol Nutr) - "PGs were more likely to have experiences using adjunctive therapy, such as racecadotril and diosmectite (aOR, 7.86; 95% CI, 1.69-36.52; p=0.009 and aOR, 15.42; 95% CI, 2.90-33.63; p<0.001, consecutively). Domperidone was mostly used for patients with the first vomiting episode (52.4%). This survey provides insight into the practices of Thai pediatricians for the management of acute diarrhea in children. Variations in the use of oral antibiotics, antiemetics, adjunctive drugs, electrolyte supplementation, and feeding were observed, which may not align with the guideline."

Clinical guideline • Journal • Pediatrics

A NEW META-ANALYTICAL DEVELOPMENT OF A PREDICTING MODEL OF CHILDREN ACUTE GASTRO-ENTERITIS OPTIMIZING THE EFFICACY ASSESSMENT OF ADJUNCT TREATMENTS. THE PRACTICAL CASE OF RACECADOTRIL (ESPGHAN 2026) - "These results necessitate further steps: the comparison of the other adjuncts must be conducted based on a similar adjusted optimized technique. Contact e-mail address [email protected]"

Clinical • Gastroenterology • Gastrointestinal Disorder • Rotavirus Infections

ROISP: Racecadotril for Organ Injury in Sepsis Patients (clinicaltrials.gov) - P1/2 | N=44 | Enrolling by invitation | Sponsor: Zhujiang Hospital | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease • Septic Shock

Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (clinicaltrials.gov) - P=N/A | N=48 | Active, not recruiting | Sponsor: Queen Mary University of London | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Respiratory Distress Syndrome • Inflammation • Pulmonary Disease • Respiratory Diseases • CXCL8

Stereoselective Bio-Organocatalytic Cascade to Chiral Amides as Active Pharmaceutical Ingredient Intermediates Using ω-Transaminase and Choline Chloride Under Microwave Irradiation. (PubMed, ChemSusChem) - "After optimizing the biocatalytic transamination in MTBE, we applied the method to the synthesis of key intermediates of Racecadotril and AVR-48, achieving full conversions and enantiomeric excess above 99%. Solvent evaporation after the transamination step was essential to remove interfering byproducts such as acetone, thus improving amidation yields. Overall, this integrated methodology provides a green, efficient, and scalable route to access amide-based building blocks in high optical purity, opening new avenues for sustainable pharmaceutical manufacturing."

Journal

Novel Deiodinase 2-Selective Inhibitors-Possible Reference Substances for Regulatory In Vitro Tests for Endocrine Disruptors and Drugs Targeting T3-Dependent Processes. (PubMed, Thyroid) - "Specific DIO2 inhibitors, such as the FDA-approved drugs racecadotril and ibrutinib and the tyrosine kinase inhibitor rociletinib, might serve as a future toolbox for reversible pharmacological interference with the local provision of DIO2-generated T3 from T4 during development, tissue regeneration, and various DIO2-dependent metabolic processes. Furthermore, they can serve as reference compounds for the development and validation of regulatory in vitro tests. Identified FDA-approved drugs warrant a closer look at potential disturbances of local TH availability."

Journal • Preclinical

ROISP: Racecadotril for Organ Injury in Sepsis Patients (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: Zhujiang Hospital

New P1/2 trial • Infectious Disease • Septic Shock

Safety and Efficacy of Racecadotril in Children With Acute Watery Diarrhea (clinicaltrials.gov) - P=N/A | N=200 | Completed | Sponsor: Punjab Rangers Teaching Hospital Lahore

New trial

Efficacy of Racecadotril in acute diarrhea in children: systematic review of double blind randomized clinical trials. (PubMed, Eur J Clin Pharmacol) - No abstract available

Clinical • Journal

Racecadotril induced bilateral uveal effusion: a case report. (PubMed, BMC Ophthalmol) - "This case of bilateral uveal effusion was probably caused by racecadotril, since this was the only recently started drug, and we observed a complete resolution of the effusion after cessation of the drug. It is possible that the increase in enkephalins caused by racecadotril intake, leads to changes in the choroid, causing choroidal effusion. It is important to recognize uveal effusion as a rare side effect of racecadotril, because of its possible sight threatening character."

Journal • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders • PENK

Combination therapy with phosphodiesterase 5 and neprilysin inhibitors synergistically offsets the development of heart failure with reduced ejection fraction (AHA 2025) - "Indeed, the expression/activity of PDEs and neprilysin are increased in pre-clinical models and patients with HFrEF.AimTo evaluate the therapeutic potential of dual inhibition of PDE5 and neprilysin in preventing the pathogenesis of HFrEF.MethodsWild type (WT), NO (GC-1α-/-) and NP (GC-A-/-) -sensitive guanylyl cyclase null mice underwent abdominal aortic constriction (AAC; increased afterload) or sham and received the PDE5 inhibitor sildenafil (Sild; 30mg/kg/day; p.o.) and/or the neprilysin inhibitor racecadotril (Race; 30mg/kg/day; p.o.). AAC elevated mRNA expression of markers of cardiac dysfunction, hypertrophy and fibrosis (e.g. BNP, Col3/4A, MMP2) which were significantly reduced by combination treatment. The positive pharmacodynamic profile of dual therapy was maintained in GC-1α-/- mice but absent in GC-A-/- animals implying efficacy was underpinned by augmentation of NP bioactivity (rather than NO).ConclusionsConcomitant blockade of PDE5 and NEP offers a novel..."

Combination therapy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • MMP2

The efficacy of lactobacillus reuteri in conjunction with racecadotril in managing pediatric rotavirus enteritis and its impact on intestinal mucosa and immune function. (PubMed, Afr Health Sci) - "There were notable changes in intestinal microbiota, with elevated Lactobacillus and Bifidobacterium levels and decreased Escherichia coli. Combining Lactobacillus reuteri and racecadotril in treating pediatric rotavirus enteritis demonstrated efficacy in regulating intestinal microbiota, alleviating mucosal barrier dysfunction, improving immune function, and enhancing treatment effectiveness."

Clinical • Journal • Gastrointestinal Disorder • Pediatrics • Rotavirus Infections • CD4 • CD8

Pharmacological and electrophysiological characterization of the novel Kv7 channel inhibitor racecadotril in Parkinson's disease. (PubMed, Neuropharmacology) - "Moreover, intraperitoneal administration of racecadotril in 8-week-old male C57BL/6 mice inhibited MPTP-induced motor dysfunction in this PD model, an effect that was blocked by the Kv7 channel opener retigabine (RTG). Taken together, our findings indicate that racecadotril is a potent inhibitor of Kv7.1, Kv7.2, Kv7.4 and Kv7.5 channels, which effectively ameliorates symptoms of PD in rodents."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Clinical practice guidelines for acute infectious diarrhea in children in China (2024). (PubMed, World J Pediatr) - "The updated guidelines address disputed treatments for acute infectious diarrhea through evidence-based revisions. Standardized etiological evaluations guide management. Probiotics are moderately advised for viral watery diarrhea; racecadotril remains unsupported. Zinc supplementation is recommended for children >6 months in deficient regions. Antibiotics are restricted to cases with dysenteric-like symptoms, suspected cholera with severe dehydration, or comorbidities."

Clinical guideline • Journal • Cholera • Gastrointestinal Disorder • Pediatrics

Racecadotril Versus Loperamide for Acute Diarrhea of Infectious Origin in Adults: A Systematic Review and Meta-Analysis. (PubMed, Health Sci Rep) - "Additionally, the analysis of secondary outcomes revealed varying effects on abdominal pain, constipation, and abdominal enlargement, with moderate heterogeneity observed (I² = 56%). Compared with loperamide, racecadotril is a better therapeutic option for adult diarrhea caused by infection."

Journal • Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pain

CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarial. (PubMed, Commun Biol) - "Interestingly, individuals in malaria-endemic regions exhibit low Kell expression and activity, indicating a plausible Plasmodium-induced evolutionary pressure. Both thiorphan and its prodrug racecadotril, demonstrated potent antimalarial activity in vivo, highlighting Kell's protease role in invasion and proposing thiorphan as a promising host-oriented antimalarial therapeutic."

Journal • Infectious Disease • Malaria

Pharmacological Strategies for High-Output Ileostomies in Children: A Narrative Review. (PubMed, Acta Paediatr) - "Pharmacological options for the treatment of HOI in children are limited and evidence for their use is lacking. Research in paediatric HOI patients is needed to validate the use of pharmacotherapy in this patient group."

Journal • Review • CNS Disorders • Pediatrics • Psychiatry

Racecadotril in the management of diarrhea: an underestimated therapeutic option? (PubMed, Therap Adv Gastroenterol) - "Racecadotril has been shown to increase the likelihood of home management of AID, to reduce hospitalizations and parenteral rehydration needs resulting in healthcare costs reduction. The current new formulations require only two-daily doses for adults and the pediatric syrup should simplify its use."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Pediatrics